Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
-$0.02 today
- Market cap
- $117.90M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
Volume 0.09M
Average 0.07M
ARMP EBITDA Margin
EBITDA as a percentage of revenue.
Armata Pharmaceuticals, Inc.AMEX: ARMP
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -13856.8%
EBITDA Margin was -13856.8% in Q1 FY2026, down 13337.0 pp from a year earlier. On a trailing-twelve-month basis it was -8872.8%, down 9159.7 pp year over year. Over 3 fiscal years it narrowed by 2521.0 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -280.4% for the fiscal year ending Dec 2026, up from -3174.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -13856.8%— QoQ
- Last fiscal yearDec 2025
- -3174.5%-3042.1 pp YoY
- LTMMar 2026
- -8872.8%-9159.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -3174.5%
- Year-over-year change
- -3042.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -3174.5% | -3042.1pp |
| FY2024 | 2024-12-31 | -132.4% | +1312.7pp |
| FY2023 | 2023-12-31 | -1445.1% | -791.5pp |
| FY2022 | 2022-12-31 | -653.5% | -163.5pp |
| FY2021 | 2021-12-31 | -490.0% | — |
EBITDA Margin vs competitors
How ARMP compares with its peers on the latest reported figures
- ARMP's LTM Mar 2026 EBITDA Margin of -8872.8% is the lowest of the 2 companies compared; the peer median is 27.2%.
- Its year-over-year change of -9159.7 pp is the lowest of 2, against a peer median of +185.8 pp.
- Over three fiscal years its change of -2521.0 pp compares with a peer median of +103.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 27.2% | +185.8 pp | +103.2 pp | |
| LTM Mar 2026 | -8872.8% | -9159.7 pp | -2521.0 pp | |
| Peer median (excluding ARMP) | 27.2% | +185.8 pp | +103.2 pp | |
Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.47M | 5.51M | 4.53M | 5.17M | 4.9M |
| Cost of Revenue | 20.02M | 35.02M | 972K | 34.43M | 1.53M |
| Gross Profit | (15.54M) | (29.51M) | 3.56M | (29.25M) | 3.37M |
| Gross Margin | -347.4% | -535.7% | 78.5% | -565.4% | 68.8% |
| Research & Development | 20.02M | 35.02M | 33.77M | 34.43M | 23.72M |
| Selling, General & Admin | 8.28M | 7.44M | 10.68M | 13.18M | 12.41M |
| Operating Expenses | 8.28M | 7.44M | 44.45M | 13.18M | 34.6M |
| Depreciation & Amortization | 1.17M | 892K | 972K | 1.33M | 1.53M |
| EBITDA | (21.92M) | (36M) | (65.45M) | (6.85M) | (155.68M) |
| EBITDA Margin | -490.0% | -653.5% | -1445.1% | -132.4% | -3174.5% |
| Operating Income | (23.82M) | (36.95M) | (40.89M) | (42.44M) | (31.22M) |
| Operating Margin | -532.5% | -670.8% | -902.8% | -820.2% | -636.7% |
| Interest Income | 5K | 29K | 179K | 697K | 388K |
| Interest Expense | 64K | 29K | 2.63M | 10.74M | 16.59M |
| Other Income / Expenses | 667K | 29K | (28.16M) | 23.52M | (142.58M) |
| Income Before Tax | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Pre-Tax Margin | -517.5% | -670.2% | -1524.5% | -365.6% | -3544.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Net Margin | -517.5% | -670.2% | -1524.5% | -365.6% | -3544.0% |
| EPS (Basic) | (0.96) | (1.08) | (1.91) | (0.52) | (4.80) |
| EPS (Diluted) | (0.96) | (1.08) | (1.91) | (0.52) | (4.80) |
| Weighted Avg Shares | 24.1M | 34.29M | 36.08M | 36.16M | 36.24M |
| Weighted Avg Shares (Diluted) | 24.1M | 34.29M | 36.08M | 36.16M | 36.24M |
Armata Pharmaceuticals, Inc.
AMEX:ARMP
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.